Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 2/2017

01-06-2017 | Review

The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases

Authors: Alfred O. Ankrah, Andor W. J. M. Glaudemans, Hans C. Klein, Rudi A. J. O. Dierckx, Mike Sathekge

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2017

Login to get access

Abstract

Human immune deficiency virus (HIV) is a leading cause of death. It attacks the immune system, thereby rendering the infected host susceptible to many HIV-associated infections, malignancies and neurocognitive disorders. The altered immune system affects the way the human host responds to disease, resulting in atypical presentation of these disorders. This presents a diagnostic challenge and the clinician must use all diagnostic avenues available to diagnose and manage these conditions. The advent of highly active antiretroviral therapy (HAART) has markedly reduced the mortality associated with HIV infection but has also brought in its wake problems associated with adverse effects or drug interaction and may even modulate some of the HIV-associated disorders to the detriment of the infected human host. Nuclear medicine techniques allow non-invasive visualisation of tissues in the body. By using this principle, pathophysiology in the body can be targeted and the treatment of diseases can be monitored. Being a functional imaging modality, it is able to detect diseases at the molecular level, and thus it has increased our understanding of the immunological changes in the infected host at different stages of the HIV infection. It also detects pathological changes much earlier than conventional imaging based on anatomical changes. This is important in the immunocompromised host as in some of the associated disorders a delay in diagnosis may have dire consequences. Nuclear medicine has played a huge role in the management of many HIV-associated disorders in the past and continues to help in the diagnosis, prognosis, staging, monitoring and assessing the response to treatment of many HIV-associated disorders. As our understanding of the molecular basis of disease increases nuclear medicine is poised to play an even greater role. In this review we highlight the functional basis of the clinicopathological correlation of HIV from a metabolic view and discuss how the use of nuclear medicine techniques, with particular emphasis of F-18 fluorodeoxyglucose, may have impact in the setting of HIV. We also provide an overview of the role of nuclear medicine techniques in the management of HIV-associated disorders.
Literature
1.
go back to reference Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016. doi:10.1016/S1473-3099(15)00485-5 Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016. doi:10.1016/S1473-3099(15)00485-5
4.
go back to reference Torre D, Speranza F, Martegani R. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med. 2005;6:66–78.CrossRefPubMed Torre D, Speranza F, Martegani R. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med. 2005;6:66–78.CrossRefPubMed
5.
go back to reference Sathekge M, Maes A, Vande WC. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43:349–66.CrossRefPubMed Sathekge M, Maes A, Vande WC. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43:349–66.CrossRefPubMed
6.
go back to reference Abdel-Dayem HM, Bag R, DiFabrizio L, Aras T, Turoglu HT, Kempf JS, et al. Evaluation of sequential thallium and gallium scans of the chest in AIDS patients. J Nucl Med. 1996;37:1662–7.PubMed Abdel-Dayem HM, Bag R, DiFabrizio L, Aras T, Turoglu HT, Kempf JS, et al. Evaluation of sequential thallium and gallium scans of the chest in AIDS patients. J Nucl Med. 1996;37:1662–7.PubMed
9.
go back to reference Scharko AM, Perlam SB, Hinds 2nd PW, Hanson JM, Uno H, Pauza CD. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci U S A. 1996;93:6425–30.CrossRefPubMedPubMedCentral Scharko AM, Perlam SB, Hinds 2nd PW, Hanson JM, Uno H, Pauza CD. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci U S A. 1996;93:6425–30.CrossRefPubMedPubMedCentral
10.
go back to reference Wallace M, Pyzalski R, Horejsh D, Brown C, Diavani M, Lu Y, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology. 2000;274:255–61.CrossRefPubMed Wallace M, Pyzalski R, Horejsh D, Brown C, Diavani M, Lu Y, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology. 2000;274:255–61.CrossRefPubMed
11.
go back to reference Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959–61.CrossRefPubMed Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959–61.CrossRefPubMed
12.
go back to reference Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet. 2003;362:945–50.CrossRefPubMed Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet. 2003;362:945–50.CrossRefPubMed
13.
go back to reference Hardy G, Worrell S, Hayes P, Barnett CM, Glass D, Pido-Lopez J, et al. Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection. HIV Med. 2004;5:67–73.CrossRefPubMed Hardy G, Worrell S, Hayes P, Barnett CM, Glass D, Pido-Lopez J, et al. Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection. HIV Med. 2004;5:67–73.CrossRefPubMed
14.
go back to reference Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985–93.CrossRefPubMed Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985–93.CrossRefPubMed
15.
go back to reference Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640–7.CrossRefPubMed Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640–7.CrossRefPubMed
16.
go back to reference Sathekge M, Maes A, Kgomo M, Van de Wiele C. Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count. Nucl Med Commun. 2010;3:137–40.CrossRef Sathekge M, Maes A, Kgomo M, Van de Wiele C. Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count. Nucl Med Commun. 2010;3:137–40.CrossRef
17.
go back to reference Tanaskovic S, Fernandez S, French MA, Price RI, Song S, Robins PD, et al. Thymic tissue is not evident on high-resolution computed tomography and [18F]fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4+ T cells. AIDS. 2011;25:1235–7.CrossRefPubMed Tanaskovic S, Fernandez S, French MA, Price RI, Song S, Robins PD, et al. Thymic tissue is not evident on high-resolution computed tomography and [18F]fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4+ T cells. AIDS. 2011;25:1235–7.CrossRefPubMed
18.
go back to reference Lelièvre JD, Melica G, Itti E, Lacabaratz C, Rozlan S, Wiedemann A, et al. Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography. J Acquir Immune Defic Syndr. 2012;61:56–63.CrossRefPubMed Lelièvre JD, Melica G, Itti E, Lacabaratz C, Rozlan S, Wiedemann A, et al. Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography. J Acquir Immune Defic Syndr. 2012;61:56–63.CrossRefPubMed
19.
go back to reference Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun. 2009;30:763–9.CrossRefPubMed Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun. 2009;30:763–9.CrossRefPubMed
20.
21.
go back to reference Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527–33.CrossRefPubMed Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527–33.CrossRefPubMed
22.
go back to reference Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR Am J Roentgenol. 2011;197:284–94.CrossRefPubMed Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR Am J Roentgenol. 2011;197:284–94.CrossRefPubMed
23.
go back to reference Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008;5:140–9.CrossRefPubMed Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008;5:140–9.CrossRefPubMed
24.
go back to reference Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.CrossRefPubMed Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.CrossRefPubMed
25.
go back to reference Bonnet F, Chêne G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol. 2008;20:534–40.CrossRefPubMed Bonnet F, Chêne G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol. 2008;20:534–40.CrossRefPubMed
26.
go back to reference Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90.CrossRefPubMed Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90.CrossRefPubMed
27.
go back to reference Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.CrossRefPubMedPubMedCentral Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.CrossRefPubMedPubMedCentral
28.
go back to reference Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF. AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis. 2008;18(2 Suppl 2):S2–189–94. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF. AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis. 2008;18(2 Suppl 2):S2–189–94.
29.
go back to reference Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.CrossRefPubMed Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.CrossRefPubMed
30.
go back to reference Moodley M, Mould S. Invasive cervical cancer and human immunodeficiency virus (HIV) infection in KwaZulu-Natal. S Afr J Obstet Gynaecol. 2005;25:706–10.CrossRef Moodley M, Mould S. Invasive cervical cancer and human immunodeficiency virus (HIV) infection in KwaZulu-Natal. S Afr J Obstet Gynaecol. 2005;25:706–10.CrossRef
31.
go back to reference Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20:1645–54.CrossRefPubMed Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20:1645–54.CrossRefPubMed
32.
go back to reference Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.CrossRefPubMedPubMedCentral Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.CrossRefPubMedPubMedCentral
33.
go back to reference Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst. 1994;86:1711–6.CrossRefPubMed Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst. 1994;86:1711–6.CrossRefPubMed
35.
go back to reference Einstein MH, Phaëton R. Issues in cervical cancer incidence and treatment in HIV. Curr Opin Oncol. 2010;22:449–55.CrossRefPubMed Einstein MH, Phaëton R. Issues in cervical cancer incidence and treatment in HIV. Curr Opin Oncol. 2010;22:449–55.CrossRefPubMed
37.
go back to reference Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127:136–40.CrossRefPubMedPubMedCentral Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127:136–40.CrossRefPubMedPubMedCentral
38.
go back to reference Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer. 2006;106:128–35.CrossRefPubMed Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer. 2006;106:128–35.CrossRefPubMed
39.
go back to reference Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78–84.CrossRefPubMedPubMedCentral Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78–84.CrossRefPubMedPubMedCentral
40.
go back to reference Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Lancet Oncol. 2009;10:1152–9.CrossRefPubMed Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Lancet Oncol. 2009;10:1152–9.CrossRefPubMed
41.
go back to reference Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116:5600–4.CrossRefPubMedPubMedCentral Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116:5600–4.CrossRefPubMedPubMedCentral
42.
go back to reference Gabarre J, Raphael M, Lepage E, Martin A, Oksenhendler E, Xerri L, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med. 2001;111:704–11.CrossRefPubMed Gabarre J, Raphael M, Lepage E, Martin A, Oksenhendler E, Xerri L, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med. 2001;111:704–11.CrossRefPubMed
43.
go back to reference Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10:1125–34.CrossRefPubMed Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10:1125–34.CrossRefPubMed
44.
go back to reference Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006;47:1326–34.PubMed Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006;47:1326–34.PubMed
45.
go back to reference Aoki Y, Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res. 2004;2:343–9.CrossRefPubMed Aoki Y, Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res. 2004;2:343–9.CrossRefPubMed
46.
go back to reference Villringer K, Jäger H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995;19:532–6.CrossRefPubMed Villringer K, Jäger H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995;19:532–6.CrossRefPubMed
47.
go back to reference Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130:662–70.CrossRefPubMed Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130:662–70.CrossRefPubMed
48.
go back to reference Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567–75.PubMed Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567–75.PubMed
49.
go back to reference Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337–46.CrossRefPubMed Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337–46.CrossRefPubMed
50.
go back to reference O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–83.PubMed O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–83.PubMed
52.
go back to reference Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol. 2003;27:1546–50.CrossRefPubMed Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol. 2003;27:1546–50.CrossRefPubMed
53.
go back to reference Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.CrossRefPubMed Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.CrossRefPubMed
54.
go back to reference Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918–24.CrossRefPubMed Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918–24.CrossRefPubMed
55.
go back to reference Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14–9.CrossRefPubMed Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14–9.CrossRefPubMed
56.
go back to reference Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085–92.CrossRefPubMed Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085–92.CrossRefPubMed
57.
go back to reference van de Luijtgaarden A, van der Ven A, Leenders W, Kaal S, Flucke U, Oyen W, et al. Imaging of HIV-associated Kaposi sarcoma; F-18-FDG-PET/CT and In-111-bevacizumabscintigraphy. J Acquir Immune Defic Syndr. 2010;54:444–6.CrossRefPubMed van de Luijtgaarden A, van der Ven A, Leenders W, Kaal S, Flucke U, Oyen W, et al. Imaging of HIV-associated Kaposi sarcoma; F-18-FDG-PET/CT and In-111-bevacizumabscintigraphy. J Acquir Immune Defic Syndr. 2010;54:444–6.CrossRefPubMed
58.
go back to reference Morooka M, Ito K, Kubota K, Minamimoto R, Shida Y, Hasuo K, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy. Jpn J Radiol. 2010;28:759–62.CrossRefPubMed Morooka M, Ito K, Kubota K, Minamimoto R, Shida Y, Hasuo K, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy. Jpn J Radiol. 2010;28:759–62.CrossRefPubMed
59.
go back to reference Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.PubMed Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.PubMed
60.
go back to reference Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging. 2009;36:648–52.CrossRefPubMed Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging. 2009;36:648–52.CrossRefPubMed
61.
go back to reference Durack DT, Street AC. Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35–51.PubMed Durack DT, Street AC. Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35–51.PubMed
62.
go back to reference Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med. 2003;253:263–75.CrossRefPubMed Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med. 2003;253:263–75.CrossRefPubMed
63.
go back to reference Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257–64.CrossRefPubMed Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257–64.CrossRefPubMed
64.
go back to reference De Munter P, Peetermans WE, Derdelinckx I, Vanderschueren S, Van Wijngaerden E. Fever in HIV-infected patients: less frequent but still complex. Acta Clin Belg. 2012;67:276–81.PubMed De Munter P, Peetermans WE, Derdelinckx I, Vanderschueren S, Van Wijngaerden E. Fever in HIV-infected patients: less frequent but still complex. Acta Clin Belg. 2012;67:276–81.PubMed
65.
go back to reference Koopmans PP, Burger DM. Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Pharm World Sci. 1998;20:253–7.CrossRefPubMed Koopmans PP, Burger DM. Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Pharm World Sci. 1998;20:253–7.CrossRefPubMed
66.
go back to reference Castaigne C, Tondeur M, de Wit S, Hildebrand M, Clumeck N, Dusart M. Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study. Nucl Med Commun. 2009;30:41–7.CrossRefPubMed Castaigne C, Tondeur M, de Wit S, Hildebrand M, Clumeck N, Dusart M. Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study. Nucl Med Commun. 2009;30:41–7.CrossRefPubMed
67.
go back to reference Martin C, Castaigne C, Tondeur M, Flamen P, De Wit S. Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study. HIV Med. 2013;14:455–62.CrossRefPubMed Martin C, Castaigne C, Tondeur M, Flamen P, De Wit S. Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study. HIV Med. 2013;14:455–62.CrossRefPubMed
69.
go back to reference Ankrah AO, van de Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Trans Imaging. 2016;4:131–41.CrossRef Ankrah AO, van de Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Trans Imaging. 2016;4:131–41.CrossRef
70.
go back to reference Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20:287–93.CrossRefPubMed Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20:287–93.CrossRefPubMed
72.
go back to reference Glaudemans AW, de Vries EF, Vermeulen LE, Slart RH, Dierckx RA, Signore A. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections. Eur J Nucl Med Mol Imaging. 2013;40:1760–9.CrossRefPubMed Glaudemans AW, de Vries EF, Vermeulen LE, Slart RH, Dierckx RA, Signore A. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections. Eur J Nucl Med Mol Imaging. 2013;40:1760–9.CrossRefPubMed
73.
go back to reference Haas H, Petrik M, Decristoforo C. An iron-mimicking, Trojan horse-entering fungi—has the time come for molecular imaging of fungal infections? PLoS Pathog. 2015;11:e1004568.CrossRefPubMedPubMedCentral Haas H, Petrik M, Decristoforo C. An iron-mimicking, Trojan horse-entering fungi—has the time come for molecular imaging of fungal infections? PLoS Pathog. 2015;11:e1004568.CrossRefPubMedPubMedCentral
74.
go back to reference Beckerman C, Bitran J. Gallium-67 scanning in the clinical evaluation of human immunodeficiency virus infection: indication and limitations. Semin Nucl Med. 1988;18:273–86.CrossRef Beckerman C, Bitran J. Gallium-67 scanning in the clinical evaluation of human immunodeficiency virus infection: indication and limitations. Semin Nucl Med. 1988;18:273–86.CrossRef
75.
go back to reference Ebenhan T, Zeevart JR, Venter JD, Govender T, Kruger GH, Jarvis NV, et al. Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin as a radioligand for PET infection imaging. J Nucl Med. 2014;55:308–14.CrossRefPubMed Ebenhan T, Zeevart JR, Venter JD, Govender T, Kruger GH, Jarvis NV, et al. Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid ubiquicidin as a radioligand for PET infection imaging. J Nucl Med. 2014;55:308–14.CrossRefPubMed
76.
go back to reference Kumar V, Boddeti DK. (68) Ga-radiopharmaceuticals for PET imaging of infection and inflammation. Recent Results Cancer Res. 2013;194:189–219.CrossRefPubMed Kumar V, Boddeti DK. (68) Ga-radiopharmaceuticals for PET imaging of infection and inflammation. Recent Results Cancer Res. 2013;194:189–219.CrossRefPubMed
77.
go back to reference Sathekge M, McFarren A, Dadachova E. Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond. Nucl Med Commun. 2014;35:792–6.PubMedPubMedCentral Sathekge M, McFarren A, Dadachova E. Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond. Nucl Med Commun. 2014;35:792–6.PubMedPubMedCentral
78.
79.
go back to reference Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(Suppl 2):115–21.CrossRefPubMed Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(Suppl 2):115–21.CrossRefPubMed
80.
go back to reference McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24:1367–70.CrossRefPubMed McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24:1367–70.CrossRefPubMed
81.
go back to reference Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med. 1996;37:1133–41.PubMed Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med. 1996;37:1133–41.PubMed
82.
go back to reference Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, Dhawan V, et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol. 1987;22:700–6.CrossRefPubMed Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, Dhawan V, et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol. 1987;22:700–6.CrossRefPubMed
83.
go back to reference van Gorp WG, Mandelkern MA, Gee M, Hinkin CH, Stern CE, Paz DK, et al. Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia. J Neuropsychiatry Clin Neurosci. 1992;4:280–7.CrossRefPubMed van Gorp WG, Mandelkern MA, Gee M, Hinkin CH, Stern CE, Paz DK, et al. Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia. J Neuropsychiatry Clin Neurosci. 1992;4:280–7.CrossRefPubMed
84.
go back to reference Hinkin CH, van Gorp WG, Mandelkern MA, Gee M, Satz P, Holston S, et al. Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci. 1995;7:180–7.CrossRefPubMed Hinkin CH, van Gorp WG, Mandelkern MA, Gee M, Satz P, Holston S, et al. Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci. 1995;7:180–7.CrossRefPubMed
85.
go back to reference von Giesen HJ, Antke C, Hefter H, Wenserski F, Seitz RJ, Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol. 2000;57:1601–7. von Giesen HJ, Antke C, Hefter H, Wenserski F, Seitz RJ, Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol. 2000;57:1601–7.
86.
go back to reference Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case–control study. Neurology. 2010;75:111–5.CrossRefPubMedPubMedCentral Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case–control study. Neurology. 2010;75:111–5.CrossRefPubMedPubMedCentral
87.
go back to reference Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol. 2012;69:72–7.CrossRefPubMedPubMedCentral Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol. 2012;69:72–7.CrossRefPubMedPubMedCentral
88.
go back to reference Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72:148–51.CrossRefPubMed Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72:148–51.CrossRefPubMed
89.
go back to reference Bartels AL, Leenders KL. Neuroinflammation in the pathophysiology of Parkinson’s disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord. 2007;22:1852–6.CrossRefPubMed Bartels AL, Leenders KL. Neuroinflammation in the pathophysiology of Parkinson’s disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord. 2007;22:1852–6.CrossRefPubMed
90.
go back to reference Samuelsson K, Pirskanen-Matell R, Bremmer S, Hindmarsh T, Nilsson BY, Persson HE. The nervous system in early HIV infection: a prospective study through 7 years. Eur J Neurol. 2006;13:283–91.CrossRefPubMed Samuelsson K, Pirskanen-Matell R, Bremmer S, Hindmarsh T, Nilsson BY, Persson HE. The nervous system in early HIV infection: a prospective study through 7 years. Eur J Neurol. 2006;13:283–91.CrossRefPubMed
91.
go back to reference Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, et al. Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm (Vienna). 2010;117:699–705.CrossRef Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, et al. Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm (Vienna). 2010;117:699–705.CrossRef
92.
go back to reference Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.CrossRefPubMed Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.CrossRefPubMed
93.
go back to reference Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57–76.CrossRefPubMed Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57–76.CrossRefPubMed
94.
go back to reference Bleeker-Rovers CP, van der Ven AJ, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, et al. F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS. 2004;18:2430–2.PubMed Bleeker-Rovers CP, van der Ven AJ, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, et al. F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS. 2004;18:2430–2.PubMed
95.
go back to reference Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun. 2010;31:311–4.CrossRefPubMed Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun. 2010;31:311–4.CrossRefPubMed
96.
go back to reference Warwick JM, Sathekge MM. PET/CT scanning with a high HIV/AIDS prevalence. Transfus Apher Sci. 2011;44:167–72.CrossRefPubMed Warwick JM, Sathekge MM. PET/CT scanning with a high HIV/AIDS prevalence. Transfus Apher Sci. 2011;44:167–72.CrossRefPubMed
97.
go back to reference Kingsley LA, Cuervo-Rojas J, Muñoz A, Palella FJ, Post W, Witt MD, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS. 2008;22:1589–99.CrossRefPubMedPubMedCentral Kingsley LA, Cuervo-Rojas J, Muñoz A, Palella FJ, Post W, Witt MD, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS. 2008;22:1589–99.CrossRefPubMedPubMedCentral
99.
go back to reference Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32(1):47–59.CrossRefPubMed Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32(1):47–59.CrossRefPubMed
100.
go back to reference Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med. 2009;50:497–500.CrossRefPubMed Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med. 2009;50:497–500.CrossRefPubMed
101.
go back to reference Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, et al. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012;9:26.CrossRef Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, et al. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012;9:26.CrossRef
102.
103.
go back to reference Tawakol A, Lo J, Zanni MV, Marmarelis E, Ihenachor EJ, MacNabb M, et al. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr. 2014;66:164–71.PubMedPubMedCentral Tawakol A, Lo J, Zanni MV, Marmarelis E, Ihenachor EJ, MacNabb M, et al. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr. 2014;66:164–71.PubMedPubMedCentral
Metadata
Title
The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases
Authors
Alfred O. Ankrah
Andor W. J. M. Glaudemans
Hans C. Klein
Rudi A. J. O. Dierckx
Mike Sathekge
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2017
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0422-0

Other articles of this Issue 2/2017

Nuclear Medicine and Molecular Imaging 2/2017 Go to the issue